X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse STRIDES PHARMA SCIENCE with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs MYLAN (US) - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STRIDES PHARMA SCIENCE   MYLAN
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
MYLAN
Dec-18
STRIDES PHARMA SCIENCE/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,1473,269-   
Low Rs6421,799-   
Sales per share (Unadj.) Rs317.21,504.3-  
Earnings per share (Unadj.) Rs7.840.8-  
Cash flow per share (Unadj.) Rs25.1322.5-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.31,627.4-  
Shares outstanding (eoy) m89.50514.50-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.81.7 167.4%   
Avg P/E ratio x114.062.0 183.8%  
P/CF ratio (eoy) x35.77.9 454.3%  
Price / Book Value ratio x3.31.6 209.4%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0581,303,893 6.1%   
No. of employees `0002.535.0 7.2%   
Total wages/salary Rs m4,3410-   
Avg. sales/employee Rs Th11,325.822,113.0 51.2%   
Avg. wages/employee Rs Th1,731.40-   
Avg. net profit/employee Rs Th280.1600.5 46.6%   
INCOME DATA
Net Sales Rs m28,394773,955 3.7%  
Other income Rs m9410-   
Total revenues Rs m29,334773,955 3.8%   
Gross profit Rs m3,965200,271 2.0%  
Depreciation Rs m1,540144,915 1.1%   
Interest Rs m1,96237,225 5.3%   
Profit before tax Rs m1,40318,132 7.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97-2,885 -3.4%   
Profit after tax Rs m70221,016 3.3%  
Gross profit margin %14.025.9 54.0%  
Effective tax rate %6.9-15.9 -43.6%   
Net profit margin %2.52.7 91.1%  
BALANCE SHEET DATA
Current assets Rs m24,836432,176 5.7%   
Current liabilities Rs m18,993315,104 6.0%   
Net working cap to sales %20.615.1 136.0%  
Current ratio x1.31.4 95.3%  
Inventory Days Days7184 84.9%  
Debtors Days Days11393 121.5%  
Net fixed assets Rs m34,289150,134 22.8%   
Share capital Rs m895412 217.2%   
"Free" reserves Rs m23,6510-   
Net worth Rs m24,546837,278 2.9%   
Long term debt Rs m15,513903,691 1.7%   
Total assets Rs m65,4372,245,905 2.9%  
Interest coverage x1.71.5 115.3%   
Debt to equity ratio x0.61.1 58.6%  
Sales to assets ratio x0.40.3 125.9%   
Return on assets %4.12.6 157.0%  
Return on equity %2.92.5 114.0%  
Return on capital %6.93.2 216.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,9620-   
CASH FLOW
From Operations Rs m1,871160,828 1.2%  
From Investments Rs m5,826-83,130 -7.0%  
From Financial Activity Rs m-10,157-74,923 13.6%  
Net Cashflow Rs m-2,6151,332 -196.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.68 Rs / USD

Compare STRIDES PHARMA SCIENCE With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare STRIDES PHARMA SCIENCE With: ALEMBIC LTD  UNICHEM LAB  PLETHICO PHARMA  WYETH LTD  CIPLA  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views On News

STRIDES PHARMA SCIENCE Plunges by 6%; BSE HEALTHCARE Index Down 0.4% (Market Updates)

Jul 17, 2019 | Updated on Jul 17, 2019

STRIDES PHARMA SCIENCE share price has plunged by 6% and its current market price is Rs 370. The BSE HEALTHCARE is down by 0.4%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 3.5%) and PFIZER (up 2.5%). The top losers is STRIDES PHARMA SCIENCE (down 5.6%)..

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati (Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance (The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 17, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS